Φορτώνει......
Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case
Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Russo |
| Έκδοση: |
IP Habib O.N.
2014-06-01
|
| Σειρά: | Современная онкология |
| Θέματα: | |
| Διαθέσιμο Online: | https://modernonco.orscience.ru/1815-1434/article/view/26969 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|